Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. The amendments herein are made without prejudice or disclaimer.

Listing of Claims:

1. (Currently amended) A method of detecting expression of mammalian CC-chemokine receptor 2 or portion thereof that includes the amino terminal domain of the receptor ~~by a cell~~, the method comprising:

a) contacting a composition comprising a cell to be tested with an antibody or antigen-binding fragment thereof which comprises six complementarity-determining regions of the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12549 or which comprises six complementarity-determining regions of the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12550 ~~binds to the amino terminal domain of said receptor~~ under conditions appropriate for binding of said antibody or fragment thereof thereto~~, wherein said antibody or antigen-binding fragment thereof inhibits binding of a chemokine to said receptor and inhibits one or more functions associated with binding of said chemokine to said receptor~~; and

b) detecting binding of said antibody or antigen-binding fragment thereof, wherein the binding of said antibody or antigen-binding fragment thereof indicates the presence of said receptor or portion of said receptor on said cell,

to thereby detect whether said cell expresses said receptor or portion of said receptor.

2. (Original) The method according to claim 1, wherein said composition is a sample comprising human cells.

3. (Original) The method according to claim 1, wherein said composition is a

sample comprising a membrane fraction of said cell to be tested.

4. (Previously presented) The method according to claim 1, wherein said mammalian CC-chemokine receptor 2 or portion thereof that includes the amino terminal domain of the receptor is a human CC-chemokine receptor 2 or portion thereof that includes the amino terminal domain of the human receptor.

5. (Original) The method according to claim 1, wherein said antibody or antigen-binding fragment thereof is labeled with a label selected from the group consisting of a radioisotope, spin label, antigen label, enzyme label, fluorescent group and chemiluminescent group.

6. (Cancel)

7. (Original) The method according to claim 1, wherein said antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.

8. (Original) The method according to claim 1, wherein said antibody or antigen-binding fragment thereof is a chimeric antibody or antigen-binding fragment thereof.

9. (Cancel)

10. (Original) The method according to claim 1, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.

11.-16. (Cancel)

17. (Previously presented) The method according to claim 10, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab

fragment, an Fab' fragment and an $F(ab')_2$ fragment.

18. (Currently amended) A method of detecting a mammalian CC-chemokine receptor 2 or portion of said receptor that includes the amino terminal domain of the receptor, comprising:

a) contacting a sample to be tested with an antibody or antigen-binding fragment thereof which comprises six complementarity-determining regions of the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12549 or which comprises six complementarity-determining regions of the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12550 ~~binds to the amino-terminal domain of said receptor~~ under conditions appropriate for binding of said antibody or fragment thereof thereto~~, wherein said antibody or antigen-binding fragment thereof inhibits binding of a chemokine to said receptor and inhibits one or more functions associated with binding of said chemokine to said receptor~~; and

b) detecting or measuring binding of said antibody or antigen-binding fragment thereof, wherein the binding of said antibody or antigen-binding fragment thereof to mammalian CC-chemokine receptor 2 or a portion thereof that includes the amino terminal domain of the receptor in said sample is indicative of the presence of a mammalian CC-chemokine receptor 2 or portion of said receptor in said sample.

19. (Original) A method according to claim 18, wherein said sample is a cellular fraction which, in normal individuals, comprises a mammalian CC-chemokine receptor 2 or portion of said receptor.

20. (Original) The method according to claim 19, wherein said cellular fraction is a membrane fraction.

21. (Original) The method according to claim 18, wherein said mammalian CC-chemokine receptor 2 or portion thereof is a human CC-chemokine receptor 2 or portion thereof.

22. (Original) The method according to claim 18, wherein said antibody or antigen-binding fragment thereof is labeled with a label selected from the group consisting of a radioisotope, spin label, antigen label, enzyme label, fluorescent group and chemiluminescent group.

23. (Cancel)

24. (Original) The method according to claim 18, wherein said antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.

25. (Original) The method according to claim 18, wherein said antibody or antigen-binding fragment thereof is a chimeric antibody or antigen-binding fragment thereof.

26. (Cancel)

27. (Original) The method according to claim 18, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.

28.-33. (Cancel)

34. (Original) The method according to claim 18, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

35.-48. (Cancelled)